Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.

被引：6
|
作者：
Patel, Jyoti D.
Le, Xiuning
Veillon, Remi
Anderson, Ian Churchill
Bestvina, Christine M.
Demedts, Ingel
Garassino, Marina Chiara
Mazieres, Julien
Morise, Masahiro
Smit, Egbert F.
Eggleton, S. Peter
OBrate, Aurora
Otto, Gordon
Bruns, Rolf
Schumacher, Karl-Maria
Paik, Paul K.
机构：
[1] Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] AZ Delta, Roeselare, Belgium
[7] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[8] CHU Toulouse, Hop Larrey, Toulouse, France
[9] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan
[10] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[11] Merck KGaA, Global Clin Dev, Darmstadt, Germany
[12] Merck KGaA, Global Med Affairs, Darmstadt, Germany
[13] Merck KGaA, Dept Biostat, Darmstadt, Germany
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9084
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION
    Bestvina, C. M.
    Patel, J. D.
    Le, X.
    Veillon, R.
    Anderson, I.
    Demedts, I.
    Garassino, M.
    Mazieres, J.
    Morise, M.
    Smit, E.
    Eggleton, S. P.
    O'Brate, A.
    Otto, G.
    Bruns, R.
    Schumacher, K. M.
    Paik, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E14 - E15
  • [2] Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Matsumoto, Shingo
    Kumagai, Toru
    Sakamoto, Tomohiro
    Tokito, Takaaki
    Atagi, Shinji
    Kozuki, Toshiyuki
    Takeoka, Hiroaki
    Chikamori, Kenichi
    Shinagawa, Naofumi
    Tanaka, Hiroshi
    Hirashima, Tomonori
    Eggleton, S. Peter
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul
    ANNALS OF ONCOLOGY, 2022, 33 : S475 - S475
  • [3] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [4] Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Le, X.
    Cho, B. C.
    Han, J-Y.
    Morise, M.
    Chen, Y-M.
    Kang, J-H.
    Kato, T.
    Takeoka, H.
    Chikamori, K.
    Sakai, H.
    Park, K.
    Wu, Y-L.
    Schumacher, K.
    Bruns, R.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1390 - S1391
  • [5] Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION Cohort A
    Thomas, M.
    Reinmuth, N.
    Wermke, M.
    Griesinger, F.
    Overbeck, T.
    Alt, J.
    Henschke, S.
    Wehler, T.
    Ochsenreither, S.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Bruns, R.
    Otto, G.
    Johne, A.
    Paik, P. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 108 - 109
  • [6] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Ahn, M-J.
    Sakai, H.
    Morise, M.
    Kato, T.
    Chen, Y-M.
    Han, J-Y.
    Yang, J-J.
    Zhao, J.
    Huang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Le, X.
    Paik, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S41 - S42
  • [7] Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC
    Griesingerl, Frank
    Garassino, Marina
    Felip, Enriqueta
    Sakai, Hiroshi
    Le, Xiuning
    Veillon, Remi
    Smit, Egbert
    Raskin, Jo
    Thomas, Michael
    Ahn, Myung-Ju
    Lee, Matthew
    Vlassak, Soetkin
    Bruns, Rolf
    Johne, Andreas
    Palle, Paul K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E37 - E38
  • [8] Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Garassino, Marina C.
    Le, Xiuning
    Iam, Wade T.
    Felip, Enriqueta
    Sakai, Hiroshi
    Veillon, Remi
    Smit, Egbert F.
    Mazieres, Julien
    Raskin, Jo
    Cortot, Alexis B.
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul K.
    CANCER RESEARCH, 2022, 82 (12)
  • [9] Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
    Garassino, M. C. C.
    Felip, E.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F. F.
    Mazieres, J.
    Cortot, A. B.
    Raskin, J.
    Thomas, M.
    Viteri, S.
    Iams, W. T.
    Kim, H. R.
    Yang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S984 - S985
  • [10] Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Viteri, S.
    Felip, E.
    Griesinger, F.
    Garassino, M. C.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F.
    Raskin, J.
    Thomas, M.
    Ahn, M-J.
    Vlassak, S.
    Bruns, R.
    Johne, A.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2023, 34
12345